These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 19135109)

  • 21. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
    Hahnova-Cygalova L; Ceckova M; Staud F
    Drug Metab Rev; 2011 Feb; 43(1):53-68. PubMed ID: 20854129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid detection of ABC transporter interaction: potential utility in pharmacology.
    Robey RW; Lin B; Qiu J; Chan LL; Bates SE
    J Pharmacol Toxicol Methods; 2011; 63(3):217-22. PubMed ID: 21112407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
    Xu J; Peng H; Zhang JT
    Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
    Hardwick LJ; Velamakanni S; van Veen HW
    Br J Pharmacol; 2007 May; 151(2):163-74. PubMed ID: 17375082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
    Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
    Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
    Haimeur A; Conseil G; Deeley RG; Cole SP
    Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
    Lemos C; Jansen G; Peters GJ
    Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
    Seamon JA; Rugg CA; Emanuel S; Calcagno AM; Ambudkar SV; Middleton SA; Butler J; Borowski V; Greenberger LM
    Mol Cancer Ther; 2006 Oct; 5(10):2459-67. PubMed ID: 17041089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of breast cancer resistance protein on cancer treatment outcomes.
    Ross DD; Nakanishi T
    Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
    Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
    Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.
    Shukla S; Schwartz C; Kapoor K; Kouanda A; Ambudkar SV
    Drug Metab Dispos; 2012 Feb; 40(2):304-12. PubMed ID: 22041108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
    Sodani K; Patel A; Anreddy N; Singh S; Yang DH; Kathawala RJ; Kumar P; Talele TT; Chen ZS
    Biochem Pharmacol; 2014 May; 89(1):52-61. PubMed ID: 24565910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABCG2: determining its relevance in clinical drug resistance.
    Robey RW; Polgar O; Deeken J; To KW; Bates SE
    Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.